TEL AVIV, Israel--(BUSINESS WIRE)--Elron Electronic Industries Ltd. (NASDAQ:ELRN) (TASE:ELRN) today announced that Medingo Ltd., a group company held 92% by Elron and its subsidiary RDC – Rafael Development Corporation Ltd., has received an informal notice, by electronic mail, that the Food and Drug Administration ("FDA") has granted clearance to market its Solo™ MicroPump Insulin Delivery System in the United States. A formal and detailed letter from the FDA has not yet been received. Elron will issue an immediate release once a formal letter is received.
